ArticleTranslational andrology and urology2026
The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin-based combination chemotherapy remains the cornerstone of treatment for advanced bladder cancer (BC). However, primary or acquired resistance following long-term use remains a critical unresolved issue in BC treatment. While accumulating evidence implicates epitranscriptomic modifications in driving chemoresistance, the precise underlying mechanisms remain incompletely elucidated. Exploring the potential mechanisms underlying cisplatin resistance in BC is crucial for identifying novel therapeutic targets and prolonging patient survival. This study aims to identify the key N6-methyladenosine (m Methods: Integrated bioinformatic analyses were performed to screen and identify critical m Results: In this study, we identified the m Conclusions: This study identifies a YTHDC1-HECW1-SMAD7 axis that regulates cisplatin resistance in BC. Targeting this axis with HDAC2 inhibitors or curcumin potentiates the anti-tumor efficacy of cisplatin, offering a promising therapeutic strategy to overcome chemoresistance in BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.